A new research has revealed that 'antibacterial resistance' may be a bigger risk factor for Cystic Fibrosis disease than perceived.
Researcher Stuart Elborn from Queen's University Belfast said that more funding and further research are required into antibiotic resistance in order to improve patient outcomes for people with Cystic Fibrosis.
Researchers stated that while not all resistance found in bacteria is caused by antibiotics, the increasing resistance to antibiotics is proving a major problem in treating people with Cystic Fibrosis.
Elborn added that while antibiotic treatment has undeniably resulted in increased life expectancy for patients with Cystic Fibrosis during the past 50 years, the emergence of antimicrobial resistance is a cause for major concern.
Elborn continued that they need to look at the use of compounds that may work against bacteria in a way that helps our current antibiotics to be more effective and such compounds are readily available for treatment of other conditions.
The study is published in The Lancet.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
